Login / Signup

Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva ® ) in Patients with Multiple Sclerosis: An Observational Retrospective Study.

Roya AbolfazliMohammad Ali SahraianAtefeh TayebiHamidreza KafiSara Samadzadeh
Published in: Journal of clinical medicine (2023)
is an effective and safe treatment option for RRMS patients in real-world practice.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • healthcare
  • primary care
  • peritoneal dialysis
  • combination therapy